In Vivo Mechanisms of Vaccine-induced Protection Against HPV Infection

Overview

Journal Cell Host Microbe

Publisher Cell Press

Specialties Infectious Diseases
Microbiology

Date 2010 Sep 14

PMID 20833377

Citations 92

Authors

Patricia M Day

Rhonda C Kines

Cynthia D Thompson

Subhashini Jagu

Richard B Roden

Douglas R Lowy

John T Schiller

Affiliations

Soon will be listed here.

Abstract

Using a human papillomavirus (HPV) cervicovaginal murine challenge model, we microscopically examined the in vivo mechanisms of L1 virus-like particle (VLP) and L2 vaccine-induced inhibition of infection. In vivo HPV infection requires an initial association with the acellular basement membrane (BM) to induce conformational changes in the virion that permit its association with the keratinocyte cell surface. By passive transfer of immune serum, we determined that anti-L1 antibodies can interfere with infection at two stages. Similarly to active VLP immunization, transfer of high L1 antibody concentrations prevented BM binding. However, in the presence of low concentrations of anti-L1, virions associated with the BM, but to the epithelial cell surface was not detected. Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo.

Citing Articles

Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.

Quang C, Anderson J, Russell F, Reyburn R, Ratu T, Tuivaga E Nat Commun. 2025; 16(1):2130.

PMID: 40032823 PMC: 11876628. DOI: 10.1038/s41467-025-57443-z.

A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection.

Bahojb Mahdavi S, Jebelli A, Aghbash P, Baradaran B, Amini M, Oroojalian F Med Res Rev. 2024; 45(2):349-425.

PMID: 39185567 PMC: 11796338. DOI: 10.1002/med.22073.

The role of HR-HPV integration in the progression of premalignant lesions into different cancer types.

Catalan-Castorena O, Garibay-Cerdenares O, Illades-Aguiar B, Rodriguez-Ruiz H, Zubillaga-Guerrero M, Leyva-Vazquez M Heliyon. 2024; 10(15):e34999.

PMID: 39170128 PMC: 11336306. DOI: 10.1016/j.heliyon.2024.e34999.

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.

Gray P, Mariz F, Eklund C, Eriksson T, Faust H, Kann H NPJ Vaccines. 2024; 9(1):146.

PMID: 39138224 PMC: 11322158. DOI: 10.1038/s41541-024-00941-w.

Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2.

Mariz F, Putzker K, Sehr P, Muller M Front Immunol. 2023; 14:1272018.

PMID: 38022617 PMC: 10663238. DOI: 10.3389/fimmu.2023.1272018.

References

Munoz N, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. DOI: 10.1093/jnci/djp534. View

Pastrana D, Buck C, Pang Y, Thompson C, Castle P, FitzGerald P . Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004; 321(2):205-16. DOI: 10.1016/j.virol.2003.12.027. View

Pereira R, Hitzeroth I, Rybicki E . Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol. 2009; 154(2):187-97. DOI: 10.1007/s00705-009-0310-3. View

Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S . Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590):890-907. DOI: 10.1016/S0140-6736(07)61416-0. View

Bernard H, Burk R, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers E . Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010; 401(1):70-9. PMC: 3400342. DOI: 10.1016/j.virol.2010.02.002. View

Day P, Lowy D, Schiller J . Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol. 2008; 82(24):12565-8. PMC: 2593329. DOI: 10.1128/JVI.01631-08. View

Cuburu N, Kweon M, Hervouet C, Cha H, Pang Y, Holmgren J . Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol. 2009; 183(12):7851-9. PMC: 7370923. DOI: 10.4049/jimmunol.0803740. View

Roberts J, Buck C, Thompson C, Kines R, Bernardo M, Choyke P . Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007; 13(7):857-61. DOI: 10.1038/nm1598. View

Kelker H, Itri V, Valentine F . A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS One. 2010; 5(1):e8555. PMC: 2797330. DOI: 10.1371/journal.pone.0008555. View

10.

Brown D, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-35. DOI: 10.1086/597307. View

11.

Carter J, Wipf G, Madeleine M, Schwartz S, Koutsky L, Galloway D . Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol. 2006; 80(10):4664-72. PMC: 1472072. DOI: 10.1128/JVI.80.10.4664-4672.2006. View

12.

Breitburd F, Kirnbauer R, Hubbert N, Nonnenmacher B, Orth G, Schiller J . Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995; 69(6):3959-63. PMC: 189126. DOI: 10.1128/JVI.69.6.3959-3963.1995. View

13.

Selinka H, Florin L, Patel H, Freitag K, Schmidtke M, Makarov V . Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol. 2007; 81(20):10970-80. PMC: 2045555. DOI: 10.1128/JVI.00998-07. View

14.

Munoz N, Bosch F, Castellsague X, Diaz M, de Sanjose S, Hammouda D . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111(2):278-85. DOI: 10.1002/ijc.20244. View

15.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

16.

Day P, Thompson C, Buck C, Pang Y, Lowy D, Schiller J . Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol. 2007; 81(16):8784-92. PMC: 1951340. DOI: 10.1128/JVI.00552-07. View

17.

Roden R, Hubbert N, Kirnbauer R, Christensen N, Lowy D, Schiller J . Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996; 70(5):3298-301. PMC: 190197. DOI: 10.1128/JVI.70.5.3298-3301.1996. View

18.

Miller C, Li Q, Abel K, Kim E, Ma Z, Wietgrefe S . Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005; 79(14):9217-27. PMC: 1168785. DOI: 10.1128/JVI.79.14.9217-9227.2005. View

19.

Ochsenbauer C, Kappes J . New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS. 2010; 4(5):418-25. DOI: 10.1097/COH.0b013e32832f011e. View

20.

Haynes B, Montefiori D . Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines. 2006; 5(3):347-63. PMC: 2716009. DOI: 10.1586/14760584.5.3.347. View